Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck KGaA Passes EXCiPACT Audit for Certification as Provider of Pharmaceutical Excipients

Published: Friday, August 02, 2013
Last Updated: Friday, August 02, 2013
Bookmark and Share
Ensures current GMP and GDP requirements applied to pharmaceutical excipients through a recognized auditing and certification process.

Merck Millipore has announced that Merck KGaA is one of the first companies to undergo and successfully complete a comprehensive EXCiPACT™ audit.

The audit ensures current GMP and GDP requirements are applied to pharmaceutical excipients through a recognized auditing and certification process covering quality management systems, manufacturing, testing and release, and storage and distribution.

This certification reduces the time and money pharmaceutical companies must invest to comply with GMP regulations and will help secure the overall excipient supply chain.

"Thousands of excipients are present in medicines and the quality of these materials is critical to ensure patient safety," said Burghard Freiberg, Senior Vice President, Pharmaceutical Chemicals Solutions, Merck Millipore.

Freiberg continued, "This EXCiPACT audit will assure our customers they are incorporating only the highest quality excipients into their formulations and we have minimized risk in their supply chains. We encourage all manufacturers of excipients to undergo the same audit."

Launched in 2012, EXCiPACT is a voluntary, international certification scheme to provide independent, third-party certification of manufacturers, suppliers and distributors of pharmaceutical excipients.

Audits conducted on behalf of the EXCiPACT association will ensure patient safety through supplier quality, while minimizing the overall costs for assessing the excipient supply chain.

EXCiPACT is a project under the International Pharmaceutical Excipients Council (IPEC) Federation, a global organization that promotes quality in pharmaceutical excipients.

"Collaborating with the EXCiPACT association to execute this audit was an important step for our company and our customers," said Matthias Bucerius, Director of Pharmaceutical Raw Materials, Merck Millipore.

Bucerius continued, "Following this positive assessment, we will undergo recertification audits every three years, with annual surveillance audits to ensure the continued safety and quality of our excipients."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Millipore Enters Into Strategic Alliance with Turgut Ilaç
Company to provide Provantage® End-to-End solution for development and manufacture of biosimilars.
Friday, October 23, 2015
Merck Millipore Introduces Enhancements to its EMPROVE® Program
Instant, online access to regulatory and technical information on portfolio of 400 products.
Thursday, September 17, 2015
Merck Millipore Enters Into Agreement with Singulex
Acquiring exclusive worldwide rights to Singulex’s SMC™ technology - instruments, assays and services - for research applications.
Thursday, May 28, 2015
Merck Millipore Announces Agreement with Precision Biologics
Merck Millipore services include design and development of cost-effective process to deliver high yield and productivity.
Thursday, February 05, 2015
Merck Millipore Expands Biomanufacturing Sciences and Training Center in Japan
Facility expansion and relocation of existing operations from Yokohama, Kanagawa Prefecture to Tokyo.
Thursday, August 28, 2014
Merck Millipore Invests €12M in France Facility
The investments will expand ready-to-use media manufacturing at company's Molshiem facility.
Tuesday, August 12, 2014
Princeton’s Dr Bonnie Bassler Receives 2014 Alice C. Evans Award
Merck Millipore congratulates winner of the Alice C. Evans award for leadership in clinical microbiology.
Thursday, May 22, 2014
Merck Millipore Announces Incoming CEO and President
Udit Batra, Ph.D. will be responsible for the organization’s strategic direction to drive growth and product innovation as well as oversight of the worldwide operations.
Tuesday, April 15, 2014
Merck Millipore, VWR Extend Western European Distribution Agreement
Provides VWR access to more Merck Millipore products and reagents for chemical and microbiological analysis.
Wednesday, April 09, 2014
Merck Millipore Introduces the Lab Solutions Virtual Conference: “Complete Solutions for Food Safety Analysis.”
Merck Millipore, the Life Science division of Merck KGaA has announced the first Lab Solutions Virtual Conference on November 19 and 20, 2013.
Tuesday, November 05, 2013
Merck Millipore Announces Co-marketing Agreement with groninger
Offering combines industry-leading single-use assemblies, sterility assurance solutions and stainless steel filling equipment.
Tuesday, August 13, 2013
Merck Millipore Partners with Gyros
Partnership to develop, manufacture and commercialize kits on the Gyrolab™ immunoassay platform.
Tuesday, July 16, 2013
Merck Millipore Opens New R&D Center
Facility fosters company's focus on Bioavailability Enhancement.
Monday, July 15, 2013
Merck Millipore Introduces the Lab Water Virtual Conference
“The Lab of Tomorrow, Bringing the Future to Life Today”.
Wednesday, May 22, 2013
Merck Millipore to Highlight LC-MS Capabilities at ASMS
Merck Millipore will highlight their new ZIC®-HILIC technology, a zwitterionic HILIC phase for LC-MS separation of polar compounds.
Monday, May 13, 2013
Scientific News
Head Injury Patients have Protein Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
Exposure to Air Pollution 30 Years Ago Associated with Increased Risk of Death
Exposure to air pollution more than 30 years ago may still affect an individual's mortality risk today, according to new research from Imperial College London.
More Then 1 in 20 U.S. Children have Dizziness and Balance Problems
Researchers at NIH have found that girls have a higher prevalence of dizziness and balance problems compared to boys, 5.7 percent and 5.0 percent.
Biosensors on Demand
New strategy results in custom "designer proteins" for sensing a variety of molecules.
Low-Cost, Portable NQR Spectroscopy
A researcher at Case Western Reserve University is developing a low-cost, portable prototype designed to detect tainted medicines and food supplements that otherwise can make their way to consumers. The technology can authenticate good medicines and supplements.
Structure of Brain Plaques in Huntington's
Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!